This study extends ADNC screening to younger patients with IDH-mutant glioma, focusing on pTau and amyloid beta (Abeta) deposits, microglial activation, and amyloid precursor protein (APP) expression in the context of cortical tumor cell infiltration.<h4>Material and methods</h4>We included 85 patients with IDH-mutant gliomas (37 astrocytomas, median age: 39; 48 oligodendrogliomas, median age: 50) classified as CNS-WHO grades 2-3. This evidence concerns the gene APP and central nervous system cancer.